Skip to content
DraconiticResearch
Search Sources API
182,469 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BY-NC-NDCancer imaging : the official publication of the International Cancer Imaging Society

Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.

  • Sohyun Park1
  • Tae-Sung Kim1
  • Sung Uk Lee2
  • Nhu Quang Tran3,4
  • Jae Young Joung5
  • Seok-Ki Kim6
6 affiliations
  1. 1Department of Nuclear Medicine, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea.
  2. 2Proton Therapy Center, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, Republic of Korea.
  3. 3Center for Urologic Cancer, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea.
  4. 4Department of Urology, Cho Ray Hospital, Ho Chi Minh City, Vietnam.
  5. 5Center for Urologic Cancer, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea. [email protected].
  6. 6Department of Nuclear Medicine, National Cancer Center, 323, Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408, Republic of Korea. [email protected].
Read full textPDFDOICite

Abstract

Background

Ga-68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) improves lesion detection in patients with biochemical recurrence (BCR) of prostate cancer. However, real-world evidence linking imaging-driven management changes to early biochemical outcomes remains limited, particularly in Korean populations. This study aimed to evaluate the impact of Ga-68 PSMA PET/CT on clinical management and its association with early biochemical response.Methods

This study included retrospectively registered 75 patients who underwent Ga-68 PSMA PET/CT for suspected BCR after radical prostatectomy between September 2022 and February 2024. Intended management at referral and final management after PET were compared. Biochemical outcomes were assessed based on follow-up prostate-specific antigen (PSA) levels.Results

Seventy-five patients were analyzed (median age, 71 years; median PSA level, 0.30 ng/mL). PSMA PET/CT demonstrated positive findings in 28 patients (37.3%), including equivocal finding. Overall, intended management was changed in 19 patients (25.3%) following PET/CT. At after 2 years of follow-up, 49 patients achieved PSA ≤ 0.20 ng/mL, and 36 achieved PSA ≤ 0.03 ng/mL.Conclusions

In prostate cancer patients with suspected BCR, Ga-68 PSMA PET/CT led to clinically meaningful changes in management and influenced treatment selection in a Korean cohort. Larger prospective studies are warranted to further define its incremental clinical value.

Related

  1. Impact of reduced scan extent on tumor detection in ⁶⁸Ga-PSMA PET/CT for biochemical recurrence of prostate cancer.
    Falk Gühne, Alexander Küppers, Christian Kühnel +2
    BMC medical imagingPeer-reviewedCC BYFull textMedical imaging & radiologyEurope PMCDOAJ
  2. Prognostic value of postoperative dynamic PNI trajectories for biochemical recurrence in patients with high-risk localized prostate cancer: a longitudinal trajectory clustering study.
    Bo Yu, Xuchao Dai, Jianguo Zhu
    Frontiers in nutritionPeer-reviewedCC BYFull textOncologyEurope PMC
  3. Current State of Adjuvant Hormone Therapy in Prostate Cancer and in the Management of Pelvic Nodal Recurrence: A Narrative Review
    Barbara D’Andrea, Antonietta Montagna, Ilaria Benevento +13
    Journal of Clinical MedicinePeer-reviewedCC BY 4.0Full textGeneral medicineCrossrefEurope PMC
  4. Transformer-Based Deep Learning Integrating Multi-Regional MRI and Clinical Features for Predicting Biochemical Recurrence After Radical Prostatectomy: A Multicenter Study.
    Mengting Zhou, Kang Lu, Yuhua Liu +6
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textMedical imaging & radiologyEurope PMC
  5. The molecular heterogeneity and clinical impact of genomic driver alterations in prostate cancer
    Diogo Pellegrina, Daria Kiriy, Kevin C. L. Cheng +58
    Nature CommunicationsPeer-reviewedCC BY-NC-ND 4.0Full textGeneral medicineCrossref

Cite

BibTeXRIS
BibTeX
@article{park2026clinical,
  title = {{Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.}},
  author = {Sohyun Park and Tae-Sung Kim and Sung Uk Lee and Nhu Quang Tran and Jae Young Joung and Seok-Ki Kim},
  journal = {Cancer imaging : the official publication of the International Cancer Imaging Society},
  year = {2026},
  month = jul,
  doi = {10.1186/s40644-026-01095-9},
  url = {https://europepmc.org/article/MED/42908003},
  note = {CC BY-NC-ND},
}
RIS
TY  - JOUR
TI  - Clinical impact of PSMA PET/CT on the management of biochemical recurrence in prostate cancer.
AU  - Sohyun Park
AU  - Tae-Sung Kim
AU  - Sung Uk Lee
AU  - Nhu Quang Tran
AU  - Jae Young Joung
AU  - Seok-Ki Kim
PY  - 2026
DA  - 2026/07/01
JO  - Cancer imaging : the official publication of the International Cancer Imaging Society
DO  - 10.1186/s40644-026-01095-9
UR  - https://europepmc.org/article/MED/42908003
AB  - Background  Ga-68 prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) improves lesion detection in patients with biochemical recurrence (BCR) of prostate cancer. However, real-world evidence linking imaging-driven management changes to early biochemical outcomes remains limited, particularly in Korean populations. This study aimed to evaluate the impact of Ga-68 PSMA PET/CT on clinical management and its association with early biochemical response.Methods  This study included retrospectively registered 75 patients who underwent Ga-68 PSMA PET/CT for suspected BCR after radical prostatectomy between September 2022 and February 2024. Intended management at referral and final management after PET were compared. Biochemical outcomes were assessed based on follow-up prostate-specific antigen (PSA) levels.Results  Seventy-five patients were analyzed (median age, 71 years; median PSA level, 0.30 ng/mL). PSMA PET/CT demonstrated positive findings in 28 patients (37.3%), including equivocal finding. Overall, intended management was changed in 19 patients (25.3%) following PET/CT. At after 2 years of follow-up, 49 patients achieved PSA ≤ 0.20 ng/mL, and 36 achieved PSA ≤ 0.03 ng/mL.Conclusions  In prostate cancer patients with suspected BCR, Ga-68 PSMA PET/CT led to clinically meaningful changes in management and influenced treatment selection in a Korean cohort. Larger prospective studies are warranted to further define its incremental clinical value.
SN  - 1740-5025
SN  - 1470-7330
ER  -